Close Menu

NEW YORK (GenomeWeb) – Leerink today initiated coverage of HTG Molecular with an Outperform rating for its stock and a target price of $6 per share.

In a note to investors, analyst Puneet Souda said that HTG has a growing funnel of biopharma partnerships and projects that have the potential to convert to US Food and Drug Administration-approved companion diagnostics and drive "significant revenue upside."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
25
Sponsored by
Roche

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.